Back to Browse Journals » Clinical Ophthalmology » Volume 2 » Issue 2

Autoimmune destruction of pericytes as the cause of diabetic retinopathy

Authors Duncan D Adams

Published 6 June 2008 Volume 2008:2(2) Pages 295—298


Duncan D Adams

Faculty of Medicine, University of Otago, Dunedin, New Zealand

Abstract: In diabetic retinopathy, collapse of the retinal vasculature is associated with loss of the pericytes. These are contractile cells that together with endothelial cells form the terminal arterioles of the retina. The cause of the loss of pericytes is not known. Recently, it has been discovered that type 1 diabetes is caused by forbidden clones of cytotoxic T lymphocytes, which destroy the insulin-making cells with exquisite specificity. In the light of this, I postulate that an antigenically-related forbidden clone of cytotoxic T lymphocytes selectively destroys the pericytes and that this is the cause of the vascular collapse of diabetic retinopathy. If this is so, the therapeutic implications are immense, involving a switch from ineffectual tight glycemic control to immunotherapy. This is already used as immunosuppression to prevent organ transplant rejection, and as the immune ablation and autologous bone marrow cell reconstitution that has saved the lives of patients with lethally-severe scleroderma. Once the pericyte surface auto-antigen for the T lymphocytes has been isolated, selective destruction of the pathogenic T lymphocytes would be possible by manufacture and use of cytotoxic auto-antigen complexes, which arrests progression of the retinopathy.

Keywords: pericytes, diabetic retinopathy, autoimmunity, T cell forbidden clones, immunotherapy

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] 


Readers of this article also read:

Current perspectives on the use of intravenous recombinant tissue plasminogen activator (tPA) for treatment of acute ischemic stroke

Chapman SN, Mehndiratta P, Johansen MC, McMurry TL, Johnston KC, Southerland AM

Vascular Health and Risk Management 2014, 10:75-87

Published Date: 24 February 2014

Safety and effectiveness of a glistening-free single-piece hydrophobic acrylic intraocular lens (enVista)

Packer M, Fry L, Lavery KT, Lehmann R, McDonald J, Nichamin L, Bearie B, Hayashida J, Altmann GE, Khodai O

Clinical Ophthalmology 2013, 7:1905-1912

Published Date: 24 September 2013

Blood pressure-independent effect of candesartan on cardio-ankle vascular index in hypertensive patients with metabolic syndrome

Kanako Bokuda, Atsuhiro Ichihara, Mariyo Sakoda, et al

Vascular Health and Risk Management 2010, 6:571-578

Published Date: 5 July 2010

Vascular calcifications as a marker of increased cardiovascular risk: A meta-analysis

R J M W Rennenberg, A G H Kessels, L J Schurgers, J M A van Engelshoven, P W de Leeuw, A A Kroon

Vascular Health and Risk Management 2009, 5:185-197

Published Date: 22 January 2009

Efficacy, safety, and improved tolerability of travoprost BAK-free ophthalmic solution compared with prior prostaglandin therapy

J Charles Henry, James H Peace, Jeanette A Stewart, William C Stewart

Clinical Ophthalmology 2008, 2:613-621

Published Date: 12 September 2008

The rate of symptomatic improvement of congenital nasolacrimal duct obstruction in Japanese infants treated with conservative management during the 1st year of age

Hirohiko Kakizaki, Yasuhiro Takahashi, Shinsuke Kinoshita, Kunihiko Shiraki, Masayoshi Iwaki

Clinical Ophthalmology 2008, 2:291-294

Published Date: 6 June 2008

Topical ophthalmic NSAIDs: a discussion with focus on nepafenac ophthalmic suspension

Bruce I Gaynes, Anne Onyekwuluje

Clinical Ophthalmology 2008, 2:355-368

Published Date: 6 June 2008

Inhaled insulin for controlling blood glucose in patients with diabetes

Bernard L Silverman, Christopher J Barnes, Barbara N Campaigne, Douglas B Muchmore

Vascular Health and Risk Management 2007, 3:947-958

Published Date: 15 January 2008

Risk reduction with clopidogrel in the management of peripheral arterial disease

Keshav R Nayak, Jeffrey J Cavendish

Vascular Health and Risk Management 2007, 3:289-297

Published Date: 15 July 2007